(Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | (FY)Dec 31, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 37.70%-987.73K | 17.05%-5.17M | 8.06%-1.3M | -36.07%-1.59M | 48.75%-6.23M | -1.41M | 28.67%-1.76M | 45.25%-1.9M | 74.67%-1.17M | -19.11%-12.16M |
Net income from continuing operations | -5.17%-1.57M | 37.60%-7.72M | 66.51%-2.46M | 14.98%-1.5M | 40.03%-12.38M | ---7.36M | 26.68%-1.91M | 67.51%-1.35M | 67.20%-1.76M | -22.19%-20.64M |
Operating gains losses | 97.09%-2.34K | 176.07%147.12K | 126.55%78.2K | -277.79%-80.32K | -16,515.29%-193.4K | ---294.52K | -3,135.24%-20.67K | 3,887.92%76.61K | 227.01%45.18K | -101.27%-1.16K |
Depreciation and amortization | -53.16%23.16K | -9.20%195.76K | -13.59%43.03K | -16.38%49.44K | -73.81%215.6K | --49.8K | -84.24%32.27K | -63.95%74.4K | -71.88%59.13K | -8.17%823.22K |
Asset impairment expenditure | ---- | -99.19%52.51K | -99.20%48.1K | ---- | 77.09%6.51M | --6.02M | ---- | ---- | ---- | 87.77%3.68M |
Remuneration paid in stock | --22.44K | 439.83%614.46K | 30.06%35.77K | --0 | -96.52%113.83K | --27.5K | 95.51%11.4K | -92.06%26.38K | -94.59%48.54K | 26.31%3.28M |
Deferred tax | ---- | --0 | ---- | ---- | -254.75%-392.85K | ---- | ---- | ---- | ---- | 69.02%-110.74K |
Other non cashItems | -9.22%223.5K | 169.92%1.22M | 52.44%440.57K | -12.57%246.19K | -63.54%451.22K | --289.01K | 42.43%271.89K | -202.47%-391.28K | -13.76%281.6K | -16.22%1.24M |
Change In working capital | 204.94%319.3K | 158.55%327.6K | 107.81%522.52K | -289.53%-304.26K | -33.63%-559.55K | --251.44K | -139.08%-641.72K | -47.97%-329.81K | 125.41%160.53K | -1,692.80%-418.73K |
-Change in receivables | 56.32%187.94K | 145.53%171.73K | 139.73%42.12K | -46.10%120.23K | 132.60%69.94K | ---106.03K | 45.52%-57.02K | -88.88%9.91K | 316.61%223.08K | -21.98%-214.53K |
-Change in inventory | ---- | --0 | --0 | ---- | 117.56%129.24K | --67.83K | 97.05%-6.28K | 178.80%115.07K | ---47.38K | ---736.16K |
-Change in prepaid assets | -171.35%-13.26K | 187.25%23.38K | -2.97%16.26K | -61.71%18.58K | -135.43%-26.8K | --16.76K | 39.45%-22.25K | 48.51%-69.84K | 149.63%48.53K | 683.60%75.63K |
-Change in payables and accrued expense | 133.36%147.82K | 118.10%132.49K | 70.09%464.14K | -595.63%-443.08K | -260.40%-731.93K | --272.88K | -748.84%-556.17K | -1,169.44%-384.95K | 85.22%-63.69K | 112.12%456.33K |
-Change in other current liabilities | ---3.2K | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 37.70%-987.73K | 17.05%-5.17M | 8.06%-1.3M | -36.07%-1.59M | 48.75%-6.23M | ---1.41M | 28.67%-1.76M | 45.25%-1.9M | 74.67%-1.17M | -19.11%-12.16M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 0 | 2,713.79%100.84K | 217.94K | -1.57K | 99.93%-3.86K | 0 | 99.41%-3.86K | 0 | 0 | -3,292.27%-5.31M |
Net PPE purchase and sale | --0 | 2,713.79%100.84K | --217.94K | ---1.57K | 99.15%-3.86K | --0 | 93.29%-3.86K | --0 | --0 | -189.09%-452.35K |
Net business purchase and sale | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---4.86M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | --0 | 2,713.79%100.84K | --217.94K | ---1.57K | 99.93%-3.86K | --0 | 99.41%-3.86K | --0 | --0 | -3,292.27%-5.31M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -78.86%706.56K | 5.39%5.29M | 229.24%840.05K | 100.24%3.34M | -69.05%5.02M | -649.99K | 29.72%3.3M | -62.02%702.87K | -70.20%1.67M | 28.30%16.23M |
Net issuance payments of debt | --0 | 74.28%-247.54K | 98.57%-9.28K | 75.96%-9.19K | -151.36%-962.24K | ---649.99K | 67.40%-10.89K | -69.81%-263.13K | -6.48%-38.22K | -55.67%1.87M |
Net common stock issuance | -62.07%768K | -27.45%4.43M | --943.25K | 39.66%2.03M | -17.01%6.1M | --0 | --3.6M | --1.05M | -49.12%1.45M | --7.35M |
Proceeds from stock option exercised by employees | --0 | 337.96%1.56M | --0 | 337.96%1.56M | -95.30%357K | --0 | --0 | --0 | -88.15%357K | -9.83%7.6M |
Net other financing activities | 74.16%-61.44K | 5.02%-448.3K | ---93.92K | -137.78%-237.78K | 19.94%-472K | --0 | ---288K | ---84K | 56.16%-100K | ---589.58K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -78.86%706.56K | 5.39%5.29M | 229.24%840.05K | 100.24%3.34M | -69.05%5.02M | ---649.99K | 29.72%3.3M | -62.02%702.87K | -70.20%1.67M | 28.30%16.23M |
Net cash flow | ||||||||||
Beginning cash position | 167.01%363.66K | -89.93%136.2K | -72.64%599.5K | -89.93%136.2K | -47.70%1.35M | --2.19M | -58.96%652.72K | -48.07%1.85M | -47.70%1.35M | 776.21%2.58M |
Current changes in cash | -116.02%-281.17K | 118.72%226.69K | 88.43%-238.29K | 248.36%1.75M | 1.76%-1.21M | ---2.06M | 367.71%1.54M | 39.43%-1.19M | -48.30%503.68K | -153.84%-1.23M |
Effect of exchange rate changes | -95.17%114 | 115.43%768 | -47.17%2.44K | 139.08%2.36K | -1,073.58%-4.98K | --4.62K | -62.37%-315 | -668.01%-3.24K | -352.57%-6.04K | -174.13%-424 |
End cash Position | -95.64%82.6K | 167.01%363.66K | 167.01%363.66K | 2.36%1.89M | -89.93%136.2K | --136.2K | 115.80%2.19M | -58.96%652.72K | -48.07%1.85M | -47.70%1.35M |
Free cash from | 37.76%-987.73K | 13.87%-5.37M | 2.07%-1.38M | -36.20%-1.59M | 50.56%-6.23M | ---1.41M | 30.15%-1.76M | 50.37%-1.9M | 74.81%-1.17M | -21.68%-12.61M |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.